دورية أكاديمية
"I wish to remain HIV negative": Pre-exposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya.
العنوان: | "I wish to remain HIV negative": Pre-exposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya. |
---|---|
المؤلفون: | Kimani M; KEMRI-Wellcome Trust Research Program, Kilifi, Kenya., van der Elst EM; KEMRI-Wellcome Trust Research Program, Kilifi, Kenya., Chirro O; KEMRI-Wellcome Trust Research Program, Kilifi, Kenya., Wahome E; KEMRI-Wellcome Trust Research Program, Kilifi, Kenya., Ibrahim F; Department of Health, Kilifi County, Kilifi, Kenya., Mukuria N; KEMRI-Wellcome Trust Research Program, Kilifi, Kenya., de Wit TFR; Department of Global Health, Amsterdam Institute for Global Health and Development, University of Amsterdam, Amsterdam, Netherlands., Graham SM; Department of Global Health, University of Washington, Seattle, Washington, United States of America., Operario D; Department of Public Health, Brown University, Providence, Rhode Island, United States of America., Sanders EJ; KEMRI-Wellcome Trust Research Program, Kilifi, Kenya.; Nufield Department of Medicine, Oxford University, Oxford, United Kingdom. |
المصدر: | PloS one [PLoS One] 2021 Jan 19; Vol. 16 (1), pp. e0244226. Date of Electronic Publication: 2021 Jan 19 (Print Publication: 2021). |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: San Francisco, CA : Public Library of Science |
مواضيع طبية MeSH: | Pre-Exposure Prophylaxis*, Anti-HIV Agents/*therapeutic use , HIV Infections/*prevention & control , Homosexuality, Male/*psychology , Transgender Persons/*psychology, Adolescent ; Adult ; Anti-HIV Agents/analysis ; Dried Blood Spot Testing ; Health Risk Behaviors ; Humans ; Interviews as Topic ; Kenya ; Male ; Medication Adherence ; Tenofovir/analysis ; Tenofovir/therapeutic use ; Young Adult |
مستخلص: | Background: Transgender women (TGW) and men who have sex with men (MSM) in sub-Saharan Africa have high HIV acquisition risks and can benefit from daily pre-exposure prophylaxis (PrEP). We assessed PrEP adherence by measuring tenofovir-diphosphate (TFV-DP) levels and explore motives for PrEP persistence in TGW and MSM. Methods: Participants were enrolled in a one-year PrEP programme and made quarterly visits irrespective of whether they were still using PrEP. At their month 6 visit, participants provided a dried blood spot to test for TFV-DP levels; protective levels were defined as those compatible with ≥4 pills per week (700-1249 fmol/punch). Before TFV-DP levels were available, a sub-set of these participants were invited for an in-depth interview (IDI). Semi-structured IDI topic guides were used to explore motives to uptake, adhere to, and discontinue PrEP. IDI data were analyzed thematically. Results: Fifty-three participants (42 MSM and 11 TGW) were enrolled. At month 6, 11 (20.7%) participants (8 MSM and 3 TGW) were lost to follow up or stopped taking PrEP. Any TFV-DP was detected in 62.5% (5/8) of TGW vs. 14.7% of MSM (5/34, p = 0.01). Protective levels were detected in 37.5% of TGW (3/8), but not in any MSM. Nineteen IDI were conducted with 7 TGW and 9 MSM on PrEP, and 1 TGW and 2 MSM off PrEP. Unplanned or frequent risky sexual risk behaviour were the main motives for PrEP uptake. Among participants on PrEP, TGW had a more complete understanding of the benefits of PrEP. Inconsistent PrEP use was attributed to situational factors. Motives to discontinue PrEP included negative reactions from partners and stigmatizing healthcare services. Conclusion: While MSM evinced greater adherence challenges in this PrEP programme, almost 40% of TGW were protected by PrEP. Given high HIV incidences in TGW these findings hold promise for TGW PrEP programming in the region. Competing Interests: The authors have declared that no competing interests exist. |
References: | J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):452-61. (PMID: 26536315) Lancet HIV. 2019 Jul;6(7):e447-e455. (PMID: 31178284) Lancet HIV. 2017 Sep;4(9):e402-e410. (PMID: 28747274) AIDS Behav. 2013 Jul;17(6):2162-72. (PMID: 23080358) AIDS Patient Care STDS. 2018 Jan;32(1):24-30. (PMID: 29185801) J Int AIDS Soc. 2019 Jul;22 Suppl 3:e25303. (PMID: 31321911) SAHARA J. 2012;9(3):160-3. (PMID: 23237071) J Int AIDS Soc. 2020 Oct;23 Suppl 6:e25591. (PMID: 33000918) N Engl J Med. 2012 Aug 2;367(5):399-410. (PMID: 22784037) J Int AIDS Soc. 2020 Jun;23 Suppl 3:e25537. (PMID: 32602658) Lancet Infect Dis. 2013 Mar;13(3):214-22. (PMID: 23260128) PLoS Med. 2019 Sep 3;16(9):e1002885. (PMID: 31479452) J Int AIDS Soc. 2020 Oct;23 Suppl 6:e25593. (PMID: 33000889) Ann Behav Med. 2014 Feb;47(1):5-16. (PMID: 24317955) Glob Public Health. 2016 Aug-Sep;11(7-8):1060-75. (PMID: 26963756) J Pharm Biomed Anal. 2016 Apr 15;122:16-20. (PMID: 26829517) J Int AIDS Soc. 2020 Oct;23 Suppl 6:e25599. (PMID: 33000907) AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90. (PMID: 22935078) Epidemiol Rev. 2004;26:22-35. (PMID: 15234945) EClinicalMedicine. 2020 Sep 09;26:100541. (PMID: 33089128) Antimicrob Agents Chemother. 2016 Oct 21;60(11):6692-6697. (PMID: 27572401) J Int AIDS Soc. 2019 Jun;22(6):e25323. (PMID: 31194291) Lancet Infect Dis. 2014 Sep;14(9):820-9. (PMID: 25065857) AIDS Care. 2016 Sep;28(9):1154-8. (PMID: 26915281) JAMA Intern Med. 2016 Jan;176(1):75-84. (PMID: 26571482) Psychoneuroendocrinology. 2012 May;37(5):662-70. (PMID: 21937168) AIDS Behav. 2020 Jul;24(7):2206-2219. (PMID: 31965432) |
معلومات مُعتمدة: | United Kingdom WT_ Wellcome Trust; R25 MH067127 United States MH NIMH NIH HHS; 107752/Z/15/Z United Kingdom WT_ Wellcome Trust |
المشرفين على المادة: | 0 (Anti-HIV Agents) 99YXE507IL (Tenofovir) |
تواريخ الأحداث: | Date Created: 20210119 Date Completed: 20210423 Latest Revision: 20220304 |
رمز التحديث: | 20240628 |
مُعرف محوري في PubMed: | PMC7815127 |
DOI: | 10.1371/journal.pone.0244226 |
PMID: | 33465090 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1932-6203 |
---|---|
DOI: | 10.1371/journal.pone.0244226 |